In a phase 3 study (MEK inhibitor in low-grade serous ovarian cancer, MILO), patients with LGSOC were randomized to treatment with the MEK inhibitor binimetinib or chemotherapy. Here, MAP2K7 is linked to ovarian serous adenocarcinoma.